DS
ORGS

David Shaw’s Orgenesis Inc. Common Stock ORGS Stock Holding History

David Shaw’s Portfolio ORGS Stock Details ORGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,505
Closed -$61K – 5611
2022
Q2 		$61K Hold
2,505
– – ﹤0.01% 4808
2022
Q1 		$87K Sell
2,505
-10
-0.4% -$304 ﹤0.01% 5028
2021
Q4 		$72K Sell
2,515
-845
-25% -$33.1K ﹤0.01% 5132
2021
Q3 		$166K Buy
+3,360
New +$169K ﹤0.01% 4610

Other funds holding ORGS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RC
Ronit Capital London, United Kingdom $74.3M AUM 13.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BHB
Bank Hapoalim BM Tel Aviv, Israel $1.5B AUM 26.39% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

David Shaw's ORGS Position: Q3 2022 in Review

David Shaw sold out of Orgenesis Inc. Common Stock (ORGS) in Q3 2022, closing a stake of 2,505 shares — an estimated $61K sold.

David Shaw first reported a position in ORGS in Q3 2021 and held it in 4 quarters. The position peaked at $166K in Q3 2021. 22 funds tracked by Wall St. Rank hold ORGS as of Q3 2022.

  • David Shaw reported no remaining Orgenesis Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • David Shaw sold 2,505 Orgenesis Inc. Common Stock shares in Q3 2022, an estimated $61K.
  • David Shaw first reported a position in Orgenesis Inc. Common Stock in Q3 2021 and held it in 4 quarters.
  • David Shaw's Orgenesis Inc. Common Stock position peaked at $166K in Q3 2021.
  • 22 funds tracked by Wall St. Rank held Orgenesis Inc. Common Stock as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.